Literature DB >> 10906770

Preparations of recombinant HIV-1 p66 antigen to improve the specificity of immune complex transfer enzyme immunoassay of antibody IgG to HIV-1 reverse transcriptase.

K Hashinaka1, I Nishikata, S Hashida, A Adachi, S Oka, E Ishikawa.   

Abstract

Recombinant HIV-1 p66 (rp66, a subunit of reverse transcriptase (RT), a heterodimer of p66 and p51) was produced in Escherichia coli in three different ways. First, rp66 was produced as a part of the fusion protein of lacZ protein and HIV-1 pol protein consisting of three components: protease (p10), RT (p51/p66), and integrase (p31), and was released from the fusion protein by the protease (pol-rp66). Second, rp66 with Ser-Ser at the N-terminus was produced as a fusion protein with maltose-binding protein containing a factor Xa site between the two proteins (MBP-Ser-Ser-rp66) and was released from the fusion protein by factor Xa (Ser-Ser-rp66). Third, rp66 with Met-Gly at the N-terminus was produced in transformed cells (Met-Gly-rp66). The recombinant proteins were purified from sonic extracts of transformed cells by ammonium sulfate fractionation and various column chromatographies. MBP-Ser-Ser-rp66 and Met-Gly-rp66 were readily purified in sufficient amounts for labeling with 2, 4-dinitrophenyl groups and beta-D-galactosidase from E. coli, but pol-rp66 and Ser-Ser-rp66 were not for enzyme-labeling. Ser-Ser-rp66 was not only polymerized but also degraded to considerable extents. The purified preparations were labeled with 2,4-dinitrophenyl groups and beta-D-galactosidase and were tested in immune complex transfer enzyme immunoassay of antibody IgG to HIV-1 RT using serum samples from 600 HIV-1 seronegative and 30 HIV-1 seropositive subjects. Among various combined uses of the two labeled preparations, the uses of 2,4-dinitrophenylated MBP-Ser-Ser-rp66 and pol-rp66 with beta-D-galactosidase-labeled Met-Gly-rp66 showed the highest (99.8%) and the second highest (99.5%) specificities, which were higher than that with the labeled preparations used in the previous study (98. 0%). Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10906770      PMCID: PMC6807956     

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  15 in total

1.  Generation and characterization of the human immunodeficiency virus type 1 mutants.

Authors:  A Adachi; N Ono; H Sakai; K Ogawa; R Shibata; T Kiyomasu; H Masuike; S Ueda
Journal:  Arch Virol       Date:  1991       Impact factor: 2.574

2.  Diagnosis of HIV-1 infection with whole saliva by detection of antibody IgG to HIV-1 with ultrasensitive enzyme immunoassay using recombinant reverse transcriptase as antigen.

Authors:  S Ishikawa; S Hashida; K Hashinaka; K Hirota; A Saitoh; A Takamizawa; H Shinagawa; S Oka; K Shimada; E Ishikawa
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1995-09-01

3.  Optimal conditions of immune complex transfer enzyme immunoassays for antibody IgGs to HIV-1 using recombinant p17, p24, and reverse transcriptase as antigens.

Authors:  S Hashida; S Ishikawa; K Hashinaka; I Nishikata; S Oka; K Shimada; A Saito; A Takamizawa; H Shinagawa; E Ishikawa
Journal:  J Clin Lab Anal       Date:  1998       Impact factor: 2.352

4.  Whole saliva dried on filter paper or diagnosis of HIV-1 infection by detection of antibody IgG to HIV-1 with ultrasensitive enzyme immunoassay using recombinant reverse transcriptase as antigen.

Authors:  S Ishikawa; S Hashida; K Hashinaka; K Hirota; M Kojima; A Saito; A Takamizawa; H Shinagawa; S Oka; K Shimada; E Ishikawa
Journal:  J Clin Lab Anal       Date:  1996       Impact factor: 2.352

5.  Ultrasensitive and rapid enzyme immunoassay (thin aqueous layer immune complex transfer enzyme immunoassay) for antibody IgG to HIV-1 p17 antigen.

Authors:  S Ishikawa; S Hashida; K Hashinaka; A Adachi; S Oka; E Ishikawa
Journal:  J Clin Lab Anal       Date:  1998       Impact factor: 2.352

6.  Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone.

Authors:  A Adachi; H E Gendelman; S Koenig; T Folks; R Willey; A Rabson; M A Martin
Journal:  J Virol       Date:  1986-08       Impact factor: 5.103

Review 7.  Enzyme-labeling of antibodies and their fragments for enzyme immunoassay and immunohistochemical staining.

Authors:  E Ishikawa; M Imagawa; S Hashida; S Yoshitake; Y Hamaguchi; T Ueno
Journal:  J Immunoassay       Date:  1983

8.  Enzyme-linked immunosorbent assays for the measurement of human immunodeficiency virus, type 1 reverse transcriptase antigen and antibodies.

Authors:  C Loveday; R S Tedder
Journal:  J Virol Methods       Date:  1993-02       Impact factor: 2.014

9.  Detection of antibody IgG to HIV-1 in urine by ultrasensitive enzyme immunoassay (immune complex transfer enzyme immunoassay) using recombinant p24 as antigen for diagnosis of HIV-1 infection.

Authors:  S Hashida; K Hashinaka; K Hirota; A Saitoh; A Nakata; H Shinagawa; S Oka; K Shimada; J Mimaya; S Matsushita
Journal:  J Clin Lab Anal       Date:  1994       Impact factor: 2.352

10.  Detection of anti-human immunodeficiency virus type 1 (HIV-1) immunoglobulin G in urine by an ultrasensitive enzyme immunoassay (immune complex transfer enzyme immunoassay) with recombinant reverse transcriptase as an antigen.

Authors:  K Hashinaka; S Hashida; K Hirota; A Saitoh; A Nakata; H Shinagawa; S Oka; K Shimada; E Ishikawa
Journal:  J Clin Microbiol       Date:  1994-03       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.